Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | MC4R | P32245 | 15/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14027063 | 0.81 | MC4R (0.61) | KCNH2MC4RLMNAHPGD | |
| SCHEMBL7206492 | 0.81 | KCNH2 (0.58) | KCNH2MC4RLMNAHPGD | |
| SCHEMBL7206481 | 0.78 | KCNH2 (0.53) | KCNH2MC4R | |
| SCHEMBL5766154 | 0.78 | KCNH2 (0.53) | KCNH2MC4RLMNAHPGD | |
| SCHEMBL4009351 | 0.77 | KCNH2 (0.56) | KCNH2MC4R | |
| SCHEMBL4008856 | 0.77 | KDM4E (0.66) | KCNH2MC4R | |
| SCHEMBL5767273 | 0.75 | MC4R (0.53) | KCNH2MC4RLMNAHPGD | |
| SCHEMBL4006667 | 0.75 | KCNH2 (0.56) | KCNH2MC4RLMNAHPGD | |
| SCHEMBL5766784 | 0.75 | KCNH2 (0.52) | KCNH2MC4RLMNAHPGD | |
| SCHEMBL5767776 | 0.75 | KCNH2 (0.52) | KCNH2MC4RLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644337-B1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | ORE PHARMACEUTICALS INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | KCNH2 3035/4885MC4R 1/4885LMNA 2506/4885 |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC1R | KCNH2 3648/4885MC4R 1/4885LMNA 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.